Orphan Drugs Offer Larger Health Gains but Less Favorable Cost-effectiveness than Non-orphan Drugs.

Chambers, James D; Silver, Madison C; Berklein, Flora C; Cohen, Joshua T; Neumann, Peter J

Chambers, James D; Silver, Madison C; Berklein, Flora C; Cohen, Joshua T; Neumann, Peter J.

Afiliação

Chambers JD; Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA. jchambers@tuftsmedicalcenter.org.
Silver MC; Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA.
Berklein FC; Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA.
Cohen JT; Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA.
Neumann PJ; Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA.

J Gen Intern Med ; 35(9): 2629-2636, 2020 09.

Article em En | MEDLINE | ID: mdl-32291711

Assuntos

Produção de Droga sem Interesse Comercial; Análise Custo-Benefício; Humanos; Anos de Vida Ajustados por Qualidade de Vida

Palavras-chave

access; cost-effectiveness; managed care; orphan drugs; rare disease

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Produção de Droga sem Interesse Comercial Tipo de estudo: Health_economic_evaluation / Prognostic_studies Limite: Humans Idioma: En Revista: J Gen Intern Med Assunto da revista: MEDICINA INTERNA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google